Baird analyst David Rescott lowered the firm’s price target on iRhythm (IRTC) to $220 from $235 and keeps an Outperform rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $205 from $195 at Morgan Stanley
- iRhythm presents new data on Zio long-term continuous ECG monitoring
- Confident Buy Rating for Irhythm Technologies Amidst LCD Concerns and Market Expansion Opportunities
- Confident Outlook for Irhythm Technologies Amid Proposed Medicare Policy Changes
- iRhythm falls -8.5%